Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Nektar (NKTR) to $192 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 earnings, and importantly updated on REZPEG’s Phase 3 ZENITH-AD program design. Accordingly, ZENITH-AD will include five total trials, with the two biologic-naive AD studies to kick-off July 2026 with first ZENITH-AD readout mid-2028. Further, ZENITH-AD includes a third trial in biologic-experienced AD patients with initiation a “few months after” biologic-naive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating
- Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
- Is NKTR a Buy, Before Earnings?
- Nektar Therapeutics Prices Upsized Public Equity Offering
- Nektar 3.5M share Secondary priced at $92.00